Literature DB >> 7518530

Different abilities of Friend murine leukemia virus (MuLV) and Moloney MuLV to induce promonocytic leukemia are due to determinants in both psi-gag-PR and env regions.

R Mukhopadhyaya1, J Richardson, V Nazarov, A Corbin, R Koller, M Sitbon, L Wolff.   

Abstract

Moloney murine leukemia virus (M-MuLV) is capable of inducing promonocytic leukemia in 50% of adult BALB/c mice that have received peritoneal injections of pristane, but Friend MuLV strain 57 (F-MuLV) is nonleukemogenic under similar conditions. It was shown earlier that these differences could not be mapped to the U3 region of the virus long terminal repeat, indicating the probable influence of structural genes and/or R-U5 sequences. In this study, reciprocal chimeras containing exchanged structural genes and R-U5 sequences from these two closely related viruses were analyzed for differences in ability to induce disease. Results showed that two regions of F-MuLV, psi-gag-PR and env, when substituted for those of M-MuLV were dramatically disease attenuating. The 5'-most region, which is widely distributed, overlaps with the 5' end of the env intron and includes the RNA packaging region, psi, the entire gag coding region, and the viral protease coding region (PR) of pol. It was also found that reciprocal constructs having substitutions of both of these regions of M-MuLV in an F-MuLV background allowed full reestablishment of promonocytic leukemia. These leukemias were positive for c-myb rearrangements which are characteristic of M-MuLV-induced promonocytic leukemias. Neither region alone, however, was sufficient to produce disease with a greater incidence than 13%. Further studies demonstrated that the inability of viruses with psi, gag, PR, or env sequences from F-MuLV to induce leukemia in this model system was not due to their inability to replicate in hematopoietic tissue, to integrate into the c-myb locus early on after infection in vivo, or to express gag-myb mRNA characteristic of M-MuLV-induced preleukemic cells and acute leukemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518530      PMCID: PMC236453     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Nucleotide sequence of Moloney murine leukaemia virus.

Authors:  T M Shinnick; R A Lerner; J G Sutcliffe
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

2.  Sequences responsible for the distinctive hemolytic potentials of Friend and Moloney murine leukemia viruses are dispersed but confined to the psi-gag-PR region.

Authors:  J Richardson; A Corbin; F Pozo; S Orsoni; M Sitbon
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

3.  Use of a focal immunofluorescence assay on live cells for quantitation of retroviruses: distinction of host range classes in virus mixtures and biological cloning of dual-tropic murine leukemia viruses.

Authors:  M Sitbon; J Nishio; K Wehrly; D Lodmell; B Chesebro
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

4.  Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses.

Authors:  B Chesebro; K Wehrly
Journal:  Virology       Date:  1985-02       Impact factor: 3.616

5.  Murine myb protooncogene mRNA: cDNA sequence and evidence for 5' heterogeneity.

Authors:  T P Bender; W M Kuehl
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  Long terminal repeats of human T-cell leukaemia virus II genome determine target cell specificity.

Authors:  I S Chen; J McLaughlin; D W Golde
Journal:  Nature       Date:  1984 May 17-23       Impact factor: 49.962

7.  Mapping the viral sequences conferring leukemogenicity and disease specificity in Moloney and amphotropic murine leukemia viruses.

Authors:  L DesGroseillers; P Jolicoeur
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

8.  A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.

Authors:  P A Chatis; C A Holland; J E Silver; T N Frederickson; N Hopkins; J W Hartley
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103

9.  Tissue-specific transcription preference as a determinant of cell tropism and leukaemogenic potential of murine retroviruses.

Authors:  D Celander; W A Haseltine
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  Role for the 3' end of the genome in determining disease specificity of Friend and Moloney murine leukemia viruses.

Authors:  P A Chatis; C A Holland; J W Hartley; W P Rowe; N Hopkins
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

View more
  6 in total

1.  Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties.

Authors:  M Audit; J Déjardin; B Hohl; C Sidobre; T J Hope; M Mougel; M Sitbon
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

2.  Mapping of a major osteomagenic determinant of murine leukemia virus RFB-14 to non-long terminal repeat sequences.

Authors:  M Ostergaard; L Pedersen; J Schmidt; A Luz; J Lovmand; V Erfle; F S Pedersen; P G Strauss
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

3.  Genetic determinant of rapid-onset B-cell lymphoma by avian leukosis virus.

Authors:  M R Smith; R E Smith; I Dunkel; V Hou; K L Beemon; W S Hayward
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

4.  An interleukin-1 beta-encoding retrovirus exhibits enhanced replication in vivo.

Authors:  Edward P Browne
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

5.  Novel integration sites at the distal 3' end of the c-myb locus in retrovirus-induced promonocytic leukemias.

Authors:  V Nazarov; L Wolff
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

6.  Mouse APOBEC3 interferes with autocatalytic cleavage of murine leukemia virus Pr180gag-pol precursor and inhibits Pr65gag processing.

Authors:  Yoshiyuki Hakata; Jun Li; Takahiro Fujino; Yuki Tanaka; Rie Shimizu; Masaaki Miyazawa
Journal:  PLoS Pathog       Date:  2019-12-12       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.